For example, osimertinib, a tyrosine kinase inhibitor, is a targeted therapy for patients with NSCLC with specific sensitizing mutations (p.Thr790Met and p.Leu858Arg) in the EGFR gene [26,27,28,29,30,31,32]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.